Key Takeaways
- •Hodgkin lymphoma
- •Post-transplant lymphoproliferative disorders (PTLD)
- •Non-Hodgkin lymphomas in HIV-positive individuals
- •T-cell and NK/T-cell lymphomas
- •Nasopharyngeal carcinoma
Epstein-Barr virus (EBV), also called human herpesvirus 4 (HHV-4), belongs to the Herpesviridae family, subfamily Gammaherpesvirinae, genus Lymphocryptovirus. First identified in 1964 in Burkitt's lymphoma, EBV provided the first clear link between an infectious agent and human cancer. Since then, it has become a model for understanding virus-host interactions, viral latency, and virus-driven oncogenesis.
A defining feature of EBV, shared with all herpesviruses, is its ability to establish lifelong persistence. EBV tightly controls host cell metabolism and alternates between two life cycle phases: a lytic phase with productive viral replication, and a latent phase where the viral genome persists as an episome in long-lived memory B cells with highly restricted gene expression.
Today, EBV is associated with a broad spectrum of diseases, including:
- Hodgkin lymphoma
- Post-transplant lymphoproliferative disorders (PTLD)
- Non-Hodgkin lymphomas in HIV-positive individuals
- T-cell and NK/T-cell lymphomas
- Nasopharyngeal carcinoma
- Certain forms of gastric cancer
Beyond malignancies, EBV causes infectious mononucleosis and oral hairy leukoplakia in immunocompromised patients. It has also been implicated in autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.
Virion Architecture and Genome Organization
Structurally, EBV closely resembles other herpesviruses. The virion has a diameter of approximately 125 nm and consists of three layers:
- A lipid envelope derived from host membranes, studded with host cell surface proteins and viral glycoproteins that determine cell tropism and mediate membrane fusion.
- A pseudo-icosahedral nucleocapsid composed of major and minor capsid proteins assembled into 150 hexamers and 11 pentamers, together with a unique portal protein.
- A pleomorphic tegument consisting of 20-40 viral proteins, positioned between envelope and capsid. Embedded within this layer is the capsid-associated tegument complex (CATC).
The EBV genome within the nucleocapsid is a linear double-stranded DNA molecule of approximately 170-180 kb, encoding 85-100 viral proteins and 44 viral microRNAs. At both termini, the genome contains two complementary regions at the ends of 538 bp terminal repeats (TRs), which anneal and ligate after infection, allowing circularization of the genome into an episome. Four internal repeat regions (IR1-IR4) divide the genome into five unique regions (U1-U5) and are closely linked to EBV's transforming ability.
Cell Tropism and Entry Pathways
EBV exhibits a pronounced tropism for pharyngeal epithelial cells and B lymphocytes, using distinct but related entry mechanisms in each cell type. This is an important consideration for peptide-based studies of viral entry and antigen presentation.
Entry into Epithelial Cells
In epithelial cells, EBV attachment is initiated by the interaction of the viral glycoprotein BMRF2 with cellular integrins via a conserved RGD (arginine-glycine-aspartate) motif. A similar integrin-binding motif in gH, as part of the gH/gL complex, further stabilizes virus-cell contact. Ultimately, gB is recruited and membrane fusion is executed by the conserved herpesviral fusion machinery formed by gH/gL and gB, allowing delivery of the nucleocapsid into the cytoplasm.
Entry into B Lymphocytes
In B cells, initial attachment is mediated by gp350/220, the most abundant viral glycoprotein, which binds complement receptors CR1 (CD35) or CR2 (CD21) on the B-cell surface. This interaction triggers endocytosis of the virion. Within the endosome, the viral glycoprotein gp42, part of the heterotrimeric gH/gL/gp42 complex, binds to the beta-chain of HLA class II molecules abundantly expressed on B cells. This interaction induces a cascade of conformational changes that enable gL to engage gB, activating gB's fusogenic activity and leading to fusion of the viral and endosomal membranes.
Note: gp350/220 are two isoforms of 350 kDa and 220 kDa with identical function. The shorter splice variant gp220 is also named gp340, reflecting historical conventions, assay-dependent detection, and differences in glycosylation.
Earliest Cytoplasmic and Nuclear Events (Pre-Latent Phase)
Inner tegument proteins, most notably BPLF1, remain in part capsid-associated and interact with the cellular cytoskeleton. Through interactions with dyneins and microtubule plus-end associated proteins (+TIPs), the nucleocapsid is actively transported toward the centrosome near the nucleus. Subsequent trafficking to the nuclear membrane is thought to resemble the mechanism described for herpes simplex virus type 1 (HSV-1), involving nuclear localization signals and interactions with the nuclear pore complex (NPC), probably mediated by BPLF1.
The delivery of viral DNA into the nucleus occurs through the nuclear pore and is driven by intracapsid pressure, analogous to genome release in bacteriophages. Once inside the nucleus, the linear EBV genome circularizes via its terminal repeats, forming a stable episome. This is the molecular foundation for EBV latency and long-term persistence.
The Pre-Latent Phase: Survival First
Although the viral genome is now maintained as an episome, transcription does not immediately follow a strictly ordered latency program. Most EBV-infected cells remain in the G0 phase of the cell cycle. During the first 1-2 weeks after infection, the viral genome is largely unmethylated, and lytic and latent genes are expressed in a partially disordered pattern. This stage is commonly referred to as the pre-latent abortive lytic phase.
While not leading to full viral replication, this phase is functionally crucial. Transient expression of lytic components, including BCL-2-like anti-apoptotic proteins and inhibitors of HLA expression, creates a protected intracellular environment. Apoptosis is suppressed, antigen presentation is reduced, and the infected cell is stabilized long enough for a structured latency program to emerge.
Establishment of Infection via Defined Promoter Usage
As transcriptional control becomes more organized, EBV gene expression shifts toward defined promoter usage. Transcription initiates at the Wp promoter cluster within the internal repeat region IR1 of the episomal genome. Wp controls expression of EBNA2 and EBNA-LP, two key transcriptional coactivators.
EBNA2 can interact with thousands of sites across the host genome. In cooperation with EBNA-LP, it suppresses transcriptional repressors, enhances transcriptional activators, and reprograms both viral and cellular gene expression. A central outcome of this reprogramming is activation of the cellular proto-oncogene MYC: EBNA2, together with EBNA-LP, probably activates an enhancer upstream of MYC.
Researchers studying these mechanisms can use peptide-based tools to dissect regulatory events at the molecular level. For those working with EBV-related compounds, our peptide glossary and reconstitution calculator may aid experimental design.